(Q43791692)

English

A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer

scientific article published in September 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

author name string

T Skovsgaard

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

N G Davidson

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

M J Piccart

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

D J Richel

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

J Bonneterre

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

D T Cirkel

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

C M Barton

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Eniluracil/Fluorouracil Breast Cancer Study Group

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

1 September 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1255-1257

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Continuous 5-fluorouracil infusion in refractory carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012249630074

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012249630074

7 January 2021

based on heuristic

inferred from DOI database lookup

5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012249630074

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012249630074

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012249630074

7 January 2021

based on heuristic

inferred from DOI database lookup

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012249630074

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012249630074

7 January 2021

based on heuristic

inferred from DOI database lookup

Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012249630074

7 January 2021

based on heuristic

inferred from DOI database lookup

5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012249630074

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012249630074

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012249630074

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012249630074

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1012249630074

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43791692&oldid=2103366406"